infohep news

• Epidemiology

  Few countries will meet 2020 target for reducing viral hepatitis deaths

  Keith Alcorn / 24 November 2020

  Around 1.1 million deaths were caused by viral hepatitis worldwide in 2019 and deaths due to hepatitis C are still rising despite the availability of direct-acting antiviral treatment, according to analyses of ...

• Antiviral therapy

  Some hepatitis B patients can safely stop antivirals

  Liz Highleyman / 24 November 2020

  Many people who take nucleoside/nucleotide antivirals for chronic hepatitis B can safely discontinue treatment, although this usually does not lead to a cure, researchers reported last week at the AASLD virtual Liver Meeting. Nucleoside/nucleotide analogues such ...

• Finance, funding & health economics

  Can investment in hepatitis C treatment be cost saving?

  Keith Alcorn / 24 November 2020

  Direct-acting antiviral treatment for hepatitis C can be cost saving for some countries within five to ten years, especially if they can negotiate lower drug prices, a study presented online at this ...

• Mother to child

  Tenofovir alafenamide prevents mother-to-child hepatitis B virus transmission

  Liz Highleyman / 20 November 2020

  Tenofovir alafenamide (TAF; Vemlidy) is highly effective at preventing transmission of hepatitis B virus (HBV) from mothers with a high viral load to their infants, according to a pair of studies presented ...

• Monitoring response to treatment

  Minimal monitoring of hepatitis C treatment is safe and effective

  Keith Alcorn / 17 November 2020

  Hepatitis C treatment with no monitoring visits during treatment is safe and leads to a high cure rate, an international study reported on Monday at the online AASLD Liver Meeting. The study was ...